Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CASR | P41180 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 6/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6566634 | 0.97 | MEN1 (0.56) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL6564786 | 0.94 | KMT2A (0.61) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL6564448 | 0.92 | MEN1 (0.50) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL6566734 | 0.91 | MAPT (0.56) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL6566837 | 0.91 | KMT2A (0.57) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL6567721 | 0.91 | KMT2A (0.54) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL6566538 | 0.90 | MEN1 (0.56) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL6564600 | 0.90 | MEN1 (0.59) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL6568011 | 0.90 | KDM4E (0.54) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL6565992 | 0.90 | MEN1 (0.53) | MEN1KMT2ALMNASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | MEN1 4143/4885KMT2A 3137/4885LMNA 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.